Literature DB >> 35594866

AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities.

J Fraser Wright1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35594866      PMCID： PMC9171258          DOI： 10.1016/j.ymthe.2022.05.004

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   12.910


× No keyword cloud information.
  5 in total

Review 1.  Leveraging rAAV bioprocess understanding and next generation bioanalytics development.

Authors:  Jose M Escandell; Daniel Am Pais; Sofia B Carvalho; Karen Vincent; Patrícia Gomes-Alves; Paula M Alves
Journal:  Curr Opin Biotechnol       Date:  2022-01-07       Impact factor: 9.740

2.  Gene therapy community grapples with toxicity issues, as pipeline matures.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2021-11       Impact factor: 84.694

3.  Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.

Authors:  Neil G Rumachik; Stacy A Malaker; Nicole Poweleit; Lucy H Maynard; Christopher M Adams; Ryan D Leib; Giana Cirolia; Dennis Thomas; Susan Stamnes; Kathleen Holt; Patrick Sinn; Andrew P May; Nicole K Paulk
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-22       Impact factor: 6.698

Review 4.  Considerations for Systemic Use of Gene Therapy.

Authors:  Barry J Byrne; Manuela Corti; Francesco Muntoni
Journal:  Mol Ther       Date:  2021-01-14       Impact factor: 11.454

5.  Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers.

Authors:  Choong-Ryoul Sihn; Britta Handyside; Su Liu; Lening Zhang; Ryan Murphy; Bridget Yates; Lin Xie; Richard Torres; Chris B Russell; Charles A O'Neill; Erno Pungor; Stuart Bunting; Sylvia Fong
Journal:  Mol Ther Methods Clin Dev       Date:  2021-12-21       Impact factor: 6.698
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.